[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 76, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2024, "totalPay": 685292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 65, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1063565, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 48, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 54000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 47, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 714747, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 61, "title": "Executive VP & CFO", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin M. Beneski", "age": 48, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 62, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 59, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 41, "title": "SVP & Corporate Controller", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.62, "open": 1.63, "dayLow": 1.63, "dayHigh": 1.8265, "regularMarketPreviousClose": 1.62, "regularMarketOpen": 1.63, "regularMarketDayLow": 1.63, "regularMarketDayHigh": 1.8265, "payoutRatio": 0.0, "beta": 0.604, "forwardPE": -2.0323825, "volume": 4665714, "regularMarketVolume": 4665714, "averageVolume": 4257170, "averageVolume10days": 6577530, "averageDailyVolume10Day": 6577530, "bid": 1.77, "ask": 1.84, "bidSize": 24, "askSize": 25, "marketCap": 404514240, "fiftyTwoWeekLow": 0.86, "fiftyTwoWeekHigh": 3.78, "allTimeHigh": 55.0, "allTimeLow": 0.86, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.5408, "twoHundredDayAverage": 1.31175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 237462256, "profitMargins": 0.0, "floatShares": 154369383, "sharesOutstanding": 224730144, "sharesShort": 18819473, "sharesShortPriorMonth": 18077704, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0837, "heldPercentInsiders": 0.1663, "heldPercentInstitutions": 0.65325, "shortRatio": 3.11, "shortPercentOfFloat": 0.1008, "impliedSharesOutstanding": 224730144, "bookValue": 1.413, "priceToBook": 1.2738854, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -212015008, "trailingEps": -0.98, "forwardEps": -0.88566, "enterpriseToEbitda": -1.118, "52WeekChange": -0.42957747, "SandP52WeekChange": 0.11471915, "quoteType": "EQUITY", "currentPrice": 1.8, "targetHighPrice": 14.0, "targetLowPrice": 1.6, "targetMeanPrice": 7.38333, "targetMedianPrice": 7.5, "recommendationKey": "none", "numberOfAnalystOpinions": 12, "totalCash": 252194000, "totalCashPerShare": 1.122, "ebitda": -212484000, "totalDebt": 85142000, "quickRatio": 7.988, "currentRatio": 8.19, "totalRevenue": 0, "debtToEquity": 27.001, "revenuePerShare": 0.0, "returnOnAssets": -0.27337998, "returnOnEquity": -0.54427, "grossProfits": -166492000, "freeCashflow": -83917752, "operatingCashflow": -158344992, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ALLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Allogene Therapeutics, Inc.", "longName": "Allogene Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1771030553, "regularMarketTime": 1771016401, "marketState": "CLOSED", "fullExchangeName": "NasdaqGS", "exchange": "NMS", "messageBoardId": "finmb_558022022", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 11.1111, "regularMarketPrice": 1.8, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539264600000, "postMarketChangePercent": -1.1111101, "postMarketPrice": 1.78, "postMarketChange": -0.01999998, "regularMarketChange": 0.18, "regularMarketDayRange": "1.63 - 1.8265", "fiftyTwoWeekRange": "0.86 - 3.78", "fiftyTwoWeekHighChange": -1.98, "fiftyTwoWeekHighChangePercent": -0.52380955, "fiftyTwoWeekChangePercent": -42.95775, "earningsTimestampStart": 1762462800, "earningsTimestampEnd": 1762462800, "earningsCallTimestampStart": 1762466400, "earningsCallTimestampEnd": 1762466400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.98, "epsForward": -0.88566, "epsCurrentYear": -0.90837, "priceEpsCurrentYear": -1.9815713, "fiftyDayAverageChange": 0.25919998, "fiftyDayAverageChangePercent": 0.16822429, "twoHundredDayAverageChange": 0.4882499, "twoHundredDayAverageChangePercent": 0.3722126, "averageDailyVolume3Month": 4257170, "fiftyTwoWeekLowChange": 0.93999994, "fiftyTwoWeekLowChangePercent": 1.0930232, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "displayName": "Allogene Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-14"}]